er-086526 and apatinib

er-086526 has been researched along with apatinib* in 1 studies

1 trial(s) available for er-086526 and apatinib

Article	Year
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nature communications, 2022, 05-31, Volume: 13, Issue:1 Topics: Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Furans; Humans; Ketones; Pyridines; Triple Negative Breast Neoplasms	2022